CALR and myeloproliferative neoplasm: A common feature, comprising over 90% of MPN cases, is the presence of a driver mutation in the genes encoding janus kinase 2 (JAK2), calreticulin (CALR), or the thrombopoietin receptor (TPOR, MPL) [1,2,3].